Pfizer to produce 120M courses of Paxlovid in 2022

Pfizer expects to produce at least 120 million courses of Paxlovid, its COVID-19 antiviral pill, in 2022, the drugmaker's CEO, Albert Bourla, PhD, said during a J.P. Morgan Healthcare Conference session Jan. 10.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive